Sodium channel blocker compositions and the use thereof

Details Sodium channel blocker compositions and the use thereof Sodium channel blocker compositions and the use thereof

2008-07-01

2008-07-01

Kwon, Brian (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S217000

Reexamination Certificate

active

10644783

ABSTRACT:
Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.

REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4602017 (1986-07-01), Sawyer et al.
patent: 4894476 (1990-01-01), Butler et al.
patent: 5025035 (1991-06-01), Wallace
patent: 5179109 (1993-01-01), Kamenka et al.
patent: 5236957 (1993-08-01), Dostert et al.
patent: 5256669 (1993-10-01), Askanazi et al.
patent: 5330515 (1994-07-01), Rutecki et al.
patent: 5446066 (1995-08-01), Varasi et al.
patent: 5449692 (1995-09-01), Varasi et al.
patent: 5660861 (1997-08-01), Jao et al.
patent: 5712277 (1998-01-01), Nakamura-Craig et al.
patent: 5741818 (1998-04-01), Dimmock
patent: 5891849 (1999-04-01), Amstutz et al.
patent: 5905069 (1999-05-01), Borsook et al.
patent: 5942510 (1999-08-01), Floyd et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6180624 (2001-01-01), Hill
patent: 6187338 (2001-02-01), Caruso et al.
patent: 6207685 (2001-03-01), Lallement et al.
patent: 6242488 (2001-06-01), Bueno et al.
patent: 6281211 (2001-08-01), Cai et al.
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6326374 (2001-12-01), Magnus et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 198 02 327 (1999-07-01), None
patent: 1 083 164 (2001-03-01), None
patent: 2 756 738 (1998-06-01), None
patent: WO 96/40628 (1996-12-01), None
patent: WO 97/05102 (1997-02-01), None
patent: WO 98/07447 (1998-02-01), None
patent: WO 98/08842 (1998-03-01), None
patent: WO 98/19674 (1998-05-01), None
patent: WO 98/19674 (1998-07-01), None
patent: WO 98/28255 (1998-07-01), None
patent: WO 98/43964 (1998-10-01), None
patent: WO 98/47869 (1998-10-01), None
patent: WO 99/12537 (1999-03-01), None
patent: WO 99/26614 (1999-06-01), None
patent: WO 99/37296 (1999-07-01), None
patent: WO 99/39712 (1999-08-01), None
patent: WO 99/44610 (1999-09-01), None
patent: WO 99/61408 (1999-12-01), None
patent: WO 00/02562 (2000-01-01), None
patent: WO 00/02592 (2000-01-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 03/020273 (2003-03-01), None
“Trigeminal Neuralgia”, www.enwikipedia.org, 2006.
“About Post-Herpetic Neuralgia”, www.aftershingles.com, 2000.
“Herpes Zoster and Postherpetic Neuralgia”, Mousey et al., American Family Physician, 2005, vol. 72. No. 6, pp. 1075-1080.
“Postthepetic Neuralgia”, Zagaria M.A., US. Pharmacist, 2002, vol. 27, No. 10.
“Treatment of Trigeminal Neuralgia at Mayo Clinic”, www.mayoclinic.org. 2006.
Backonja, M., et al., “Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus,”JAMA280:1831-1836, The American Medical Association (Dec. 1998).
Bennett, G.J., “Neuropathic Pain: An Overview,” inMolecular Neurobiology of Pain9:109-113, Borshook, D., ed., IASP Press, Seattle (1997).
Bensimon, G., et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis,”New England J. Med.330:585-591, The Massachusetts Medical Society (1994).
Beydoun, A., “Postherpetic Neuralgia: Role of Gabapentin and Other Treatment Modalities,”Epilepsia40(Suppl.6) :S51-S56, Lippincott Williams & Wilkins (Oct. 1999).
Blinder, B.J., et al., “Advances in Mood Stabilizing Medications,”West. J. Med.169:39-40, BMJ Publishing (1998).
Boyce, S., et al., “Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn,”Neuropharmacology38:611-623, Pergamon and Elsevier Science Ltd. (May 1999).
Brown, C.M., et al., “Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia,”British J. Pharmacol.115:1425-1432, Stockton Press (1995).
Bryans, J.S., and Wustrow, D.J., “3-Substituted GABA Analogs with Central Nervous System Activity: A Review,”Med. Res. Rev.19:149-177, John Wiley & Sons, Inc. (Mar. 1999).
Buchan, A.M., et al., “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?,”Supplement I, Stroke24:Il48-Il52, American Heart Association (1993).
Canavero, S., et al., “The riddle of trigeminal neuralgia,”Pain60:229-231, Elsevier Science B.V. (1995).
Carrazana, E.J., and Schachter, S.C., “Alternative uses of lamotrigine and gabapentin in the treatment of trigeminal neuralgia,”Neurology50:1192, The American Academy of Neurology (Apr. 1998).
Catterall, W.A., “Common modes of drug action on Na+ channels: local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci.8:57-65, Elsevier Science Publishers B.V. (1987).
Catterall, W.A., “Neurotoxins That Act on Voltage-sensitive Sodium Channels on Excitable Membranes,”Ann. Rev. Pharmacol. Toxicol.20:15-43, Annual Reviews Inc. (1980).
Catterall, W.A., “Structure and Function of Voltage-Sensitive Ion Channels,”Science242:50-61, The American Association for the Advancement of the Science (1988).
Chapman, V., et al., “Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats,”Pain75:261-272, Elsevier Science B.V. (Apr. 1998).
Creveling, C.R., et al., “Batrachotoxin-Induced Depolarization and [3H] Batrachotoxinin-A 20 α-Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex,”Mol. Pharmacol.23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983).
Czuczwar, S.J., and Przesmycki, K., “Felbamate, Gabapentin and Topiramate as Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy,”Polish J. Pharmacol.53:65-68, Polish Academy of Sciences (2001).
De Sarro, G., et al., “Gabapentin Potentiates the Antiseizure Activity of Certain Anticonvulsants in DBA/2 Mice,”Eur. J. Pharmacol.349:179-185, Elsevier Science (1998).
Denicoff, K.D., et al., “Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey,”J. Clin. Psychiatry55:70-76, Physicians Postgraduate Press, Inc. (1994).
Dichter, M.A., et al., “Drug Therapy: New Antiepileptic Drugs,”New Engl. J. Med.334:1583-1590, Massachusetts Medical Society (1996).
Field, M.J., et al., “Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat,”Pain80:391-398, Elsevier Science B.V. (Mar. 1999).
Goldberg, I., and Green, B., “Focus on Gabapentin,”Focus8:1-6, Priory Lodge Education Ltd. (1997) from http://www.priory.com/focus8.htm.
Graham, S.H., et al., “A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia,”J. Pharmacol. Exp. Therap.276:1-4, Williams & Wilkins (1996).
Graham, S.H., et al., “Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion,”J. Pharmacol. Exp. Therp.269:854-859, Williams & Wilkins (1994).
Gurney, et al., “Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis,”Ann. Neurol.39:147-157, The American Neurological Association (1996).
Hamill, O.P., et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pfluegers Arch391:85-100, Springer International (1981).
Hoekstra, M.S., et al., “Chemical Development of CI-1008, an Enantiomerically Pure Anticonvulsant,”Org. Process Res. Dev.1:26-38, American Chemical Society and Royal Society of Chemistry (1997).
Hunskaar, S., et al., “Formalin tes

Affiliated with

Also associated with

Rating

Sodium channel blocker compositions and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sodium channel blocker compositions and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium channel blocker compositions and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3921967